Fulcrum Therapeutics, Inc. vs CytoMed Therapeutics Limited — Valuation Comparison 2026
Access all valuation models for FULC vs GDTC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →FULC scores higher with a 6.5/10 quality rating vs GDTC's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Fulcrum Therapeutics, Inc. (FULC) and CytoMed Therapeutics Limited (GDTC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
FULC currently trades at $6.82 with a QOC of 6.5/10, while GDTC trades at $1.14 with a QOC of 5.1/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).